Page 5 - Mankind Pharma

Stock of this pharma company has nearly doubled against its issue price

Mankind hit record high of Rs 2,132.10, rallied 8% in intra-day trade and zoomed 97% against its issue price of Rs 1,080 per share.

Battery recycling startup BatX Energies raises $5 mn in early stage funding

Battery recycling startup BatX Energies on Tuesday said it raised USD 5 million (over Rs 40 crore) in an early stage funding round led by Zephyr Peacock. Lets Venture as well as existing investors JITO Angel Network and family offices of Mankind Pharma, Excel Industries, and BluSmart also participated in the pre-Series A funding round, BatX Energies said in a statement. The infusion of fresh funds will help scale up recycled battery-grade lithium, nickel and cobalt production and establish a secured nationwide reverse logistics network for sourcing, it added. "Through strategic allocation of these funds, we're poised to power our vision of sustainable energy solutions. We're directing resources towards pioneering R&D initiatives, elevating the production of superior battery-grade materials," BatX Energies Co-founder & CTO Vikrant Singh said. He further said, "This investment propels our mission to expand globally and establish micro facilities nationwide, fostering a future ...

3 PE firms offload 7.9% in Mankind; Motisons Jewellers IPO to open Dec 18

The deals took place at around Rs 1,832 apiece. Shares of Mankind fell 3.6 per cent to close at Rs 1,849

Stocks to Watch: Sun Pharma, Infosys, Dixon, DLF, Mankind Pharma, SpiceJet

Stocks to watch on December 12, 2023: Sun Pharma has increased its offer price for acquiring remaining shares of Taro Pharma to $43 per share in cash, compared to $38 before

Mankind Pharma surges 5%, Flair Writing sets price band of Rs 288-304

Besides Flair, the company's products are sold under brands such as Hauser, Pierre Cardin and Zoox

Mankind Pharma sees 21% profit surge in Q2 despite consumer health hurdles

The delayed season not only affected anti-infectives but also related sub-therapies such as respiratory, cough and cold, gastro, and vitamins, says Juneja

Street signs: Bulls charge ahead, IPO stars shine bright, and more

Shares of Mankind Pharma, SBFC Finance, and Fusion Micro Finance are likely to attract attention as the lock-in periods related to their initial public offerings (IPOs) come to an end

Stocks to Watch: Bharti Airtel, L&T, Tata Motors, Ethos, Blue Jet, Mankind

Stocks to watch on November 1, 2023: Bank of Baroda's head of digital lending, Akhil Handa, a techie closely associated with building the mobile banking application 'bob World', has quit

Mankind Pharma Q2 results: Consolidated net profit rises 21% to Rs 511 cr

Mankind Pharma on Tuesday said its consolidated net profit increased by 21 per cent to Rs 511 crore for the second quarter ended September 30, 2023, on the back of robust performance across segments. The company had reported a net profit of Rs 422 crore in the July-September period of the last fiscal. Revenue from operations rose to Rs 2,708 crore in the period under review from Rs 2,425 crore in the year-ago period, Mankind Pharma said in a regulatory filing. "The past strategic choices in various aspects of our business are showing success, and we are confident in our ability to consistently surpass the industry growth in future," Mankind Pharma Vice Chairman & Managing Director Rajeev Juneja said. Shares of Mankind Pharma on Tuesday ended 0.7 per cent lower at Rs 1,741.10 apiece on the BSE.

ChrysCapital bullish on future of tech, pharma and financial services

The firm worked closely with ManKind Pharma and ran an internal cost reduction program which saved them close to Rs 100 crores

RR Kabel IPO subscribed 25% on day 1, price band at Rs 983 to Rs 1,035

The fresh issue component of the IPO is only Rs 180 crore and the remaining is secondary share sale by promoters and TPG

Mankind Pharma PAT up 66% in Q1 to Rs 494 crore on revenue growth

Juneja also highlighted a 43 per cent YoY increase in Ebitda as a positive outcome of the company's previous initiatives to improve profitability

Stocks to Watch today, July 5: LTIMindtree, Bandhan Bk, Lupin, Adani Power

Stocks to Watch on Wednesday, July 5: LTIMindtree will replace HDFC in the benchmark Nifty50 index, while LIC Housing Finance will likely replace it in the Nifty Financial Services index

Mankind Pharma's success boosts hopes of more consumer IPOs in India

The company, which raised Rs 4,330 crore ($528 million) in India's second-largest new share sale this year, has seen its shares jump 57% in almost two months, drawing a rush of buy calls from analysts

Up almost 32% since listing, Mankind Pharma draws rush of 'buys'

The company's stock has surged more than 60 per cent since listing, driving its market value to about $8.5 billion

Street signs: Mkts turn skittish near new highs, Index fund inflows & more

The benchmark indices registered declines in the previous two trading sessions, which could be a bearish sign, observe analysts

Pharmacists have finger on pulse of small towns as demand increases

The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) is another major reason for the growth in demand for medicines in smaller towns

Mankind Pharma scales new high; rallies 11% in 3 days post Q4 earnings beat

Currently, the stock was quoting 40 per cent higher over its issue price of Rs 1,080.

Stocks to watch: Coal India, Mankind Pharma, EID Parry, India Pesticides

Stocks to watch on June 1, 2023: From Coal India to Mankind Pharma, here are top stocks to watch in Thursday's trading session

Mankind Pharma's profit after tax up 52% at Rs 294 cr in March quarter

Mankind Pharma on Wednesday reported 52 per cent increase in consolidated profit after tax (PAT) at Rs 294 crore for March quarter 2022-23, aided by robust sales. The company had logged a PAT of Rs 193 crore in January-March 2021-22. Revenue from operations rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period, Mankind Pharma said in a statement. In 2022-23, the PAT declined 10 per cent to Rs 1,310 crore from Rs 1,453 crore in the previous year. "The company maintained its strong growth trajectory during the year..our consumer healthcare business has maintained its double-digit growth with dominant brand leadership in its categories," Mankind Pharma Vice Chairman and Managing Director Rajeev Juneja said. Earlier this month, the Income Tax Department conducted raids on the premises of the company over allegations of tax evasion.